Giant Biogene (02367) saw its shares rise more than 4% during the trading session. At the time of writing, the stock was up 2.4% to HK$25.56, with a turnover of HK$46.32 million.

The movement follows recent news where the company announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., received a Class III Medical Device Registration Certificate from China's National Medical Products Administration for its "Cross-linked Recombinant Collagen Implant."

The product utilizes the full-length sequence of human type III mature collagen, comprising 1,068 amino acids, which fully retains the natural functional domains of collagen. It employs a physical cross-linking process that carries no risk of residual chemical cross-linking agents, forming a stable three-dimensional network gel. It is intended for intradermal injection into the dermis of the neck for filling purposes to correct moderate to severe horizontal neck lines.

Analysis points out that the approval of this Class III medical device, the "Cross-linked Recombinant Collagen Filler," is significant as it represents the world's first cross-linked recombinant full-length type III collagen filler approved for the neck wrinkle indication, giving it a distinct competitive advantage. Furthermore, the company's first approved aesthetic medicine product was officially launched on June 9, and its cosmetics business is showing signs of accelerating growth. There is a positive outlook on the improving fundamentals of the company, suggesting attention to potential opportunities at current levels.